Top Enroller for Regeneron Phase III Trial Enrolls 300+ Chicago Patients (CCRI)

by PRC Agency PR

Chicago Clinical Research Institute, Inc. is sharing news of their latest successes and research developments in the global battle against Covid-19. CCRI collaborated with Regeneron and Paraxel to conduct a Phase III clinical trial for the treatment of Covid-19 and for post-exposure prophylaxis (prevention) of COVID-19. The study was successfully completed, and the drug, REGEN-COV, received FDA approval.

This findings of this study was also published in the New England Journal of Medicine .

https://www.nejm.org/doi/full/10.1056/NEJMoa2108163

As a leading clinical research site, in the fight against the Covid-19, Chicago Clinical Research Institute has previously collaborated with AstraZeneca for a Covid-19 prophylaxis study, which radically altered the approach of the medical community in the US to the disease. Chicago Clinical Research Institute has also collaborated with Sanofi Pasteur on another Covid-19 vaccine study enrolling 141 subjects in one study. CCRI research efforts have helped pave the way for the mass vaccination rollouts which have taken place internationally.

With well over 1 million deaths recorded from the virus in the United States alone, WHO and the global health community remain attuned to its complexities and its ongoing implications for public health. Chicago Clinical Research Institute believes it is imperative that American medical institutions and key industry figures remain vigilant and continue to learn from SARS-CoV-2; understanding that the adaptable SARS strain may continue to mutate and may precipitate further pandemics of a similar nature.

As such, the organization is proud to detail to fellow Contract Research Organizations (CRO), pharmaceutical companies, and sponsors the results of their most recent Phase III clinical trial to contribute their findings to this critical pool of ongoing research.

Chicago Clinical Research Institute in partnership with AstraZeneca and IQVIA enrolled 275 subjects for a Covid-19 Prophylaxis study AZD7442 (prevention of Covid-19). Based upon the prophylactic and therapeutic effects it had displayed in the treatment of SARS-CoV-2 in animal models, CCRI proceeded with single-dose intramuscular testing within their patient sample.

The preliminary conclusions of the trial indicate that you can implement a single dose of AZD7442 for the prevention of Covid-19, for a median period of at least six months.

CCRI’s Principal Investigator, Dr. Dennis J. Levinson, was listed as an author of the research paper titled ‘Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19’, which has now been published in The New England Journal of Medicine.

https://www.nejm.org/doi/full/10.1056/NEJMoa2116620

A spokesperson for the medical researchers said, “The data that resulted from our most recent trial provides support for the use of AZD7442 as immunoprophylaxis to prevent Covid-19. The primary efficacy analysis and the key supportive analyses met the statistical criterion for trial success. The incidences of symptomatic RT-PCR-positive SARS-CoV-2 infection and severe disease among infected participants were lower in the AZD7442 group than in the placebo group, and there were no evident safety concerns.”

Chicago Clinical Research Institute, Inc. was founded in 2008. CCRI is research site that conducts phase I to phase IV clinical trials independently and by partnering with major CROs and pharmaceutical sponsors globally. Beyond their ground-breaking work in the fight against Covid-19, they conduct research on innovative treatments for various therapeutic areas like Type II Diabetes, Cardiovascular Disease, Neurodegenerative Disease, and Osteoarthritis.

Chicago Clinical Research Institute believes it is incumbent upon the health and research community to continue learning from the 21st century’s most significant medical event.

Visit https://ccrii.us/cont